Afrezza (MNKD) - Long-Term Debt to Capital Coefficient

Afrezza - graphic logo of issuer MNKD

The price history of MannKind Corporation (MNKD) reflects the dynamics of a company whose success is based on owning a unique powder inhalation system for diabetics and protected patents. The current figure is 0.00. The business relies on the high cost of its solutions due to the lack of alternatives to injections, while operational efficiency is enhanced by outsourcing logistics and trials to external contractors.

MannKind Corp (MNKD): Long-Term Debt to Equity from 07/04/2022 to 11/01/2026

Comprehensive metric breakdowns and analytics for MannKind Corporation (MNKD)

- stock price and consensus target price:
Quote Chart MannKind Corp|MNKD - Analyst Consensus Forecast
- market capitalization indicators:
Market Value MannKind Corporation|MNKD - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share MannKind|MNKD - Company Book Value|Market Value to Book Value mannkindcorp.com|MNKD - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio MannKind Corporation|MNKD - Long-Term Debt to Capital|Short-Term Debt to Capital mannkindcorp.com|MNKD - Company Total Debt|Debt to Net Assets Ratio MannKind Corporation|MNKD - Company Long-Term Debt|Short-Term Debt MannKind|Intermediate Liquidity Ratio mannkindcorp.com
- net income and valuation ratios data:
MNKD - Net Profit
General company analysis:MannKind Corp - MNKD
Signature product of MannKind Corporation

The selection of defensive assets is based on minimal debt load, which is critical for MannKind Corporation (MNKD) during its expansion into the growing inhalation diabetes therapy segment. The long-term debt-to-equity ratio measures the proportion of loans with a maturity of over one year within the capital structure, allowing investors to assess balance sheet stability and the company's ability to fund growth without the risk of default.

Analysis of competing companies

Haleon PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital KVUE|VRNA (Verona Pharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|Long-Term Debt to Capital ligand.com LGND|AMRX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Liquidia Inc.|GLPG (Galapagos NV) - Long-Term Debt to Capital|Long-Term Debt to Capital anipharmaceuticals.com|Long-Term Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Long-Term Liabilities to Capital|AQST: Long-Term Debt to Equity Ratio|scPharmaceuticals Inc. - Long-Term Loans to Capital Ratio|TECX: Long-Term Debt to Capital|Tonix Pharma - Long-Term Debt to Capital Coefficient|SXTC (SXT Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Eupraxia Pharma EPRX|Long-Term Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Oramed Pharmaceuticals Inc. ORMP|ENTX - Long-Term Debt to Equity Ratio|MindWalk - Long-Term Debt to Capital|ABVC - Long-Term Debt to Capital|Cumberland Pharmaceuticals (CPIX) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio QNTM|Long-Term Debt to Equity FibroGen|Long-Term Debt to Capital Ratio TELO (Telomir Pharmaceuticals Inc)|Long-Term Debt to Equity Rani Therapeutics (RANI)|Long-Term Debt to Capital synergychc.com (SNYR)|Long-Term Debt to Capital RLYB (Rallybio)|Ratio of Long-Term Indebtedness to Capital Lexaria Bioscience Corp (LEXX)|PULM - Long-Term Debt to Equity|PTHL (Pheton Holdings Ltd) - Long-Term Debt to Capital Ratio|APM: Long-Term Debt to Capital|Long-Term Debt to Capital Ratio LYRA|Long-Term Debt to Equity Ratio IBO|TNFA: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital YCBD|Long-Term Debt to Equity Ratio PainReform Ltd PRFX|Long-Term Debt to Equity Altamira Therapeutics Ltd. CYTO|Lipella Pharma (LIPO) - Long-Term Liabilities to Capital|OPTN - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PIRS (pieris.com)|Procaps (PROC) - Long-Term Debt to Equity|Long-Term Liabilities to Equity PTPI (Petros Pharmaceuticals Inc)|Long-Term Debt to Equity Qilian International Holding Group Limited|Long-Term Liabilities to Capital ACELYRIN Inc. SLRN|Long-Term Debt to Equity TFF Pharmaceuticals (TFFP)